In
the first nine months of the year, fundraising -- mostly in
later stage rounds -- reached $7.5 billion, close to the amount
raised in all of 2019.
"This quarter foreign investors allocated the highest amounts of
all time," said Shmulik Zysman, managing partner at ZAG. "The
total capital invested by Israeli funds is also the highest
ever."
Life science firms stood out in the third quarter, as one in
four deals was from this sector.
Early-stage companies have been affected by the pandemic, with
investors focusing on later stage companies, he said. Less than
$100 million was raised by 95 seed deals so far this year.
"There is still more than enough money at the Israeli dedicated
venture capital funds, but their appetite for risks has
declined," said Marianna Shapira, IVC research director.
(Reporting by Tova Cohen; Editing by Steven Scheer)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.
|
|